290 related articles for article (PubMed ID: 31131678)
1. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
2. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
3. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
Eksteen B; Bowlus CL; Montano-Loza AJ; Lefebvre E; Fischer L; Vig P; Martins EB; Ahmad J; Yimam KK; Pockros PJ; Feld JJ; Minuk G; Levy C
Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
[TBL] [Abstract][Full Text] [Related]
5. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
[TBL] [Abstract][Full Text] [Related]
6. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
7. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
9. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.
Tabibian JH; Gossard A; El-Youssef M; Eaton JE; Petz J; Jorgensen R; Enders FB; Tabibian A; Lindor KD
Am J Ther; 2017; 24(1):e56-e63. PubMed ID: 24914504
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.
Talwalkar JA; Angulo P; Keach JC; Petz JL; Jorgensen RA; Lindor KD
Am J Gastroenterol; 2005 Feb; 100(2):308-12. PubMed ID: 15667487
[TBL] [Abstract][Full Text] [Related]
11. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.
Bakhshi Z; Hilscher MB; Gores GJ; Harmsen WS; Viehman JK; LaRusso NF; Gossard AA; Lazaridis KN; Lindor KD; Eaton JE
J Gastroenterol; 2020 May; 55(5):523-532. PubMed ID: 31932891
[TBL] [Abstract][Full Text] [Related]
12. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.
Eaton JE; Vesterhus M; McCauley BM; Atkinson EJ; Schlicht EM; Juran BD; Gossard AA; LaRusso NF; Gores GJ; Karlsen TH; Lazaridis KN
Hepatology; 2020 Jan; 71(1):214-224. PubMed ID: 29742811
[TBL] [Abstract][Full Text] [Related]
13. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis.
Liu X; Wang H; Liu X; Bridle K; Crawford D; Liang X
Pharmacol Ther; 2022 Sep; 237():108163. PubMed ID: 35271884
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.
Bharucha AE; Jorgensen R; Lichtman SN; LaRusso NF; Lindor KD
Am J Gastroenterol; 2000 Sep; 95(9):2338-42. PubMed ID: 11007239
[TBL] [Abstract][Full Text] [Related]
16. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.
Al Mamari S; Djordjevic J; Halliday JS; Chapman RW
J Hepatol; 2013 Feb; 58(2):329-34. PubMed ID: 23085647
[TBL] [Abstract][Full Text] [Related]
17. Short-term prognostic factors for primary sclerosing cholangitis.
Watanabe T; Hirano K; Tada M; Isayama H; Mizuno S; Arizumi T; Toda N; Sugawara Y; Kokudo N; Koike K
J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of etanercept in the treatment of primary sclerosing cholangitis.
Epstein MP; Kaplan MM
Dig Dis Sci; 2004 Jan; 49(1):1-4. PubMed ID: 14992426
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.
Van Thiel DH; Carroll P; Abu-Elmagd K; Rodriguez-Rilo H; Irish W; McMichael J; Starzl TE
Am J Gastroenterol; 1995 Mar; 90(3):455-9. PubMed ID: 7532912
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Hatami B; Mosala M; Hassani AH; Ardakani MJE; Gholami S; Zali MR
Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
